In utero treatment of toxoplasmic fetopathy with the combination pyrimethamine-sulfadiazine.
The mothers of 52 fetuses with toxoplasma fetopathy diagnosed in utero were treated with a combination pyrimethamine-sulfa drug and spiramycine. Their infants were compared to a group of 51 infants whose mothers had received spiramycine alone. Postnatal treatment was identical in both groups. Parasitological investigation of the placenta was positive in 42 and 76.6%; the newborns had a specific IgM of 17.4 and 69% in groups 1 and 2, respectively. These differences were significant. The mean specific IgG titer was significantly reduced at birth and at 4-6 months of age in group 1. According to the results obtained in the present material the pyrimethamine-sufa drug combination, given to the mothers of fetuses infected with toxoplasma, has a significant effect on the parasitological and serological signs of evolutive fetopathy. It did not significantly alter the clinical pattern, probably because the onset of treatment was too long after maternal infection.
Couvreur
J
J
Institut de Puériculture, Paris, France.
Thulliez
P
P
Daffos
F
F
Aufrant
C
C
Bompard
Y
Y
Gesquière
A
A
Desmonts
G
G
D000913:Antibodies, Protozoan / Q000097:blood; D004338:Drug Combinations; D005260:Female; D005315:Fetal Diseases / Q000188:drug therapy* / Q000276:immunology / Q000469:parasitology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011739:Pyrimethamine / Q000008:administration & dosage*; D015572:Spiramycin / Q000008:administration & dosage; D013411:Sulfadiazine / Q000008:administration & dosage*; D014125:Toxoplasmosis, Congenital / Q000188:drug therapy* / Q000276:immunology / Q000469:parasitology
D000913:Antibodies, Protozoan; D004338:Drug Combinations; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D013411:Sulfadiazine; D015572:Spiramycin; D011739:Pyrimethamine